Company news
Recce Pharmaceuticals Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Cleansing Notice
November 16, 2026
Application for quotation of securities - RCE
November 16, 2026
Notification regarding unquoted securities - RCE
November 13, 2026
Final Director's Interest Notice - Mr McKeough
November 6, 2026
Results of Meeting
November 5, 2026
AGM Presentation
November 5, 2026
Retirement of Mr Alistair McKeough as Non-Executive Director
November 4, 2026
Options Prospectus
November 3, 2026
Cleansing Notice
October 30, 2026
Application for quotation of securities - RCE
October 30, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
License and Commercialisation Agreement in AUS/NZ for R327G
October 21, 2026
License and Commercialisation Agreement in AUS/NZ for R327G
October 21, 2026
Independent Review of Indonesian Phase 3 R327G Trial Data
October 19, 2026
Independent Review of Indonesian Phase 3 R327G Trial Data
October 19, 2026
Notification regarding unquoted securities - RCE
October 16, 2026
Amendments to Debt Facility with Avenue Capital Group
October 16, 2026
Amendments to Debt Facility with Avenue Capital Group
October 16, 2026
Notice of Annual General Meeting/Proxy Form
October 6, 2026
Notification of cessation of securities - RCE
October 1, 2026
Resolutions under section 249N of the Corporations Act
September 29, 2026
2026 Annual General Meeting
September 18, 2026
Results of General Meeting
September 1, 2026
General Meeting Presentation
September 1, 2026
Appendix 4E and FY26 Annual Report
August 31, 2026
Appendix 4G
August 31, 2026
HREC Approves Comparator Study for Pivotal Phase 3 DFI
August 18, 2026
Change of Director's Interest Notices (x4)
August 6, 2026
Cleansing Notice
August 4, 2026
Application for quotation of securities - RCE
August 2, 2026
Completion of Share Purchase Plan and Shortfall Notice
July 30, 2026
Application for quotation of securities - RCE
July 30, 2026
Notice of General Meeting/Proxy Form
July 30, 2026
U.S. Government Releases US$66.9B AMR Biodefense Strategy
July 29, 2026
Vietnamese Patent Granted for RECCE Anti-Infectives
July 13, 2026
AUD $3.7M Income Tax Refund Received
June 30, 2026
Placement & SPP to raise $8 million
June 25, 2026
HREC Approval Accelerates Global Phase 3 DFI Strategy
June 21, 2026
Addendum to Recce Signs Middle East Licensing Term Sheet
May 27, 2026
Recce Signs Middle East Licensing Term Sheet
May 26, 2026
Brazil Patent Granted for RECCE Anti-Infectives
March 24, 2026
RCE Investor Webinar Presentation Deck
March 19, 2026
Appendix 4D and Interim Financial Report
February 27, 2026
Recce Enters Second U.S. Department of Defense R&D Agreement
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2026
AUD $5.3m R&D Rebate Received
January 13, 2026
RCE Awarded Advanced Overseas Finding up to A$85m
December 15, 2025
Hong Kong Patent Granted for RECCE Anti-Infectives
November 26, 2025
Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
November 25, 2025
Decks
The 5 newest of 45 decks. Every deck is listed under its year.
- Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides · Nov 6, 2026
- Investor Presentation (November 2026)
Investor deck · 45 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 42 slides · October 2026
- Shareholder Meeting (September 2026)
Shareholder meeting · 10 slides · Sep 2, 2026
- Investor Presentation (September 2026)
Investor deck · 42 slides · September 2026